Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients.

Details

Ressource 1Download: 35805050_BIB_3EF953BEBC36.pdf (338.24 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_3EF953BEBC36
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients.
Journal
Cancers
Author(s)
Dos Santos Q., Wareham N.E., Mocroft A., Rasmussen A., Gustafsson F., Perch M., Sørensen S.S., Manuel O., Müller N.J., Lundgren J., Reekie J.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
04/07/2022
Peer-reviewed
Oui
Volume
14
Number
13
Pages
3279
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Post-transplant lymphoproliferative disease (PTLD) is a well-recognized complication after transplant. This study aimed to develop and validate a risk score to predict PTLD among solid organ transplant (SOT) recipients. Poisson regression identified predictors of PTLD with the best fitting model selected for the risk score. The derivation cohort consisted of 2546 SOT recipients transpanted at Rigshospitalet, Copenhagen between 2004 and 2019; 57 developed PTLD. Predictors of PTLD were high-risk pre-transplant Epstein-Barr Virus (EBV), IgG donor/recipient serostatus, and current positive plasma EBV DNA, abnormal hemoglobin and C-reactive protein levels. Individuals in the high-risk group had almost 7 times higher incidence of PTLD (incidence rate ratio (IRR) 6.75; 95% CI: 4.00-11.41) compared to the low-risk group. In the validation cohort of 1611 SOT recipients from the University Hospital of Zürich, 24 developed PTLD. A similar 7 times higher risk of PTLD was observed in the high-risk group compared to the low-risk group (IRR 7.17, 95% CI: 3.05-16.82). The discriminatory ability was also similar in derivation (Harrell's C-statistic of 0.82 95% CI (0.76-0.88) and validation (0.82, 95% CI:0.72-0.92) cohorts. The risk score had a good discriminatory ability in both cohorts and helped to identify patients with higher risk of developing PTLD.
Keywords
EBV DNA, PTLD, SOT, transplantation
Pubmed
Web of science
Open Access
Yes
Create date
19/07/2022 9:53
Last modification date
23/01/2024 8:23
Usage data